Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nerandomilast versus placebo in systemic sclerosis
PACTR202609848231002Phase 3Not yet recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in systemic sclerosis (SSc) comparing Nerandomilast + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Time to all-cause death or disease progression. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
nerandomilast
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on PACTR202609848231002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202609848231002.